| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Licensing and collaboration revenue ( from related party for the three months ended xxx, respectively) | 2,198 | 2,667 | 2,353 | 2,024 |
| Research and development | 22,401 | 27,692 | 35,531 | 30,421 |
| General and administrative | 9,197 | 10,403 | 9,735 | 9,841 |
| Impairment charges | 0 | 12,150 | - | - |
| Total operating expenses | 31,598 | 50,245 | 45,266 | 40,262 |
| Loss from operations | -29,400 | -47,578 | -42,913 | -38,238 |
| Change in fair value of equity securities | - | - | - | -14 |
| Impairment of equity investment | 0 | -9,158 | - | - |
| Change in fair value of the mskcc success payments liability | 0 | -451 | -334 | 164 |
| Other income, net | 1,852 | 2,187 | 2,588 | 3,732 |
| Total other income (expense) | 1,852 | -6,520 | 2,922 | 3,554 |
| Net loss | -27,548 | -54,098 | -39,991 | -34,684 |
| Net unrealized gain (loss) on available-for-sale marketable securities, net of tax | 53 | -127 | -88 | 1,108 |
| Net comprehensive loss | -27,495 | -54,225 | -40,079 | -33,576 |
| Net loss per share, basic (in dollars per share) | -0.3 | -0.58 | -0.43 | -0.38 |
| Net loss per share, diluted (in dollars per share) | -0.3 | -0.58 | -0.43 | -0.38 |
| Weighted-average common shares outstanding, basic (in shares) | 93,293,099 | 93,028,698 | 92,679,493 | 90,455,900 |
| Weighted-average common shares outstanding, diluted (in shares) | 93,293,099 | 93,028,698 | 92,679,493 | 90,455,900 |
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)